DiscoveryDecember12th,2020By Mel J. YeatesA new way to view wet AMDNew insights into age-related macular degeneration could lead to better treatments
November17th,2020By Mel J. YeatesmiRagen brings in Viridian TherapeuticsThe acquisition includes clinical stage anti-IGF-1R monoclonal antibody VRDN-001, which is intended for treatment of thyroid eye disease
November17th,2020By DDN StaffVanda gains IND approval for CFTR activator VSJ-110Vanda Pharmaceuticals gains FDA approval on their IND for VSJ-110 to treat allergic conjunctivitis
June23rd,2020By Mel J. YeatesResearchers discover astrocytes could be behind nerve deathAstrocytes could play a critical role in nerve death in neurodegenerative diseases
June17th,2020By Mel J. YeatesInvestigating stromal vascular fraction therapy for COVID-19San Diego Academy of Regenerative Therapies publishes article about first-in-human clinical trial using adipose-derived SVF to treat post-COVID-19 patients suffering lung damage
May31st,2020By Kelsey KaustinenOptimal OPTICsADVM-022 demonstrates efficacy, durability in OPTIC trial in wet AMD
May31st,2020By DDN StaffUsher updateProQR offers upbeat interim analysis in Phase 1/2 trial of QR-421a for Usher Syndrome
April2nd,2020By Kelsey KaustinenWorking toward a broad-spectrum therapyOcugen’s gene therapy candidate shows potential in five different models of retinitis pigmentosa
January13th,2020By DDNews StaffModels for seeing things more clearlyTwo new cell models for ocular drug discovery could reduce the need for animal testing
January12th,2020By Kelsey KaustinenADVM-022 success is no OPTICal illusionAdverum’s wet AMD candidate helps maintain vision in Phase 1 trial